2021 CMSC Annual Meeting

Tag: 7297DMT26Poster-Disease-modifying TherapyElizabeth A Douglas

Poster-Disease-modifying Therapy

Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data

Background: Ocrelizumab (OCR) is a humanized, monoclonal antibody targeting CD20+ B cells and is approved for treatment of relapsing...

Read More